Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) covers the month of March 2025, specifically reporting on a share repurchase transaction executed on February 28, 2025. The filing details a transaction in the company's own shares conducted through its corporate stockbroker, Citigroup Global Markets Limited, as part of an existing buyback programme.
Key Financial Metrics
The filing focuses exclusively on capital allocation activities regarding share repurchases. No revenue, profit, cash flow, margin, debt, or liquidity metrics are provided in this specific document.
- Shares Purchased (Feb 28, 2025): 542,550 ordinary shares
- Price Range: 1,462.50p (Low) to 1,478.50p (High)
- Volume-Weighted Average Price: 1,469.84p
- Total Shares Purchased Since Feb 24, 2025: 3,953,602 ordinary shares
- Treasury Shares Held: 173,023,905
- Ordinary Shares in Issue (Excluding Treasury): 4,142,153,525
- Total Voting Rights: 4,142,153,525
Material Changes
The filing reports a reduction in the number of shares in issue due to the acquisition of treasury shares. Since the commencement of the current non-discretionary agreement on February 24, 2025, the company has purchased nearly 4 million shares. The specific transaction on February 28, 2025, added 542,550 shares to the company's treasury holdings.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks described in GSK's 2023 Annual Report on Form 20-F and Q4 2024 results. The purchase was executed pursuant to a non-discretionary agreement, indicating a structured approach to capital return.
Investor Verification Checklist
- Verify the total remaining authorization under the existing buyback programme to assess future repurchase capacity.
- Confirm the impact of the 173,023,905 treasury shares on earnings per share (EPS) calculations in upcoming financial reports.
- Review the non-discretionary agreement terms announced on February 24, 2025, to understand the duration and volume constraints of the current buyback phase.
- Check the latest Form 20-F or Q4 2024 results for the broader context of liquidity and debt levels supporting these repurchases.